CV Sciences, Inc. Highlights Recent Research Showing Cannabidiol May Reduce Relapses in Smokeless Tobacco Addiction

LAS VEGAS, NV -- (Marketwired) -- 08/15/17 -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company," "CV Sciences," "our" or "we") highlighted a recent study conducted at Federal University of Prana and Santa Catarina in Brazil which reports that preclinical and clinical studies suggested that cannabidiol (CBD) may help prevent drug addiction relapse. The research cites the effects of CBD drugs on the aversive and rewarding drug-associated memory extinction and reconsolidation, inhibiting the CB1 receptor to suppress reinstatement of drug rewarding memories.

The CB1 receptor in the endocannabinoid system plays an important role in emotional memory processing, including emotional rewards from addictive drugs such as nicotine. Stimulation of the CB1 receptor seems to facilitate the initiation and maintenance of addiction, in turn affecting the likelihood of relapses of drug addiction after achieving abstinence. CBD, acting as an inverse agonist, is the most potent cannabinoid inhibitor of CB1. This inhibition of CB1 seems to help extinguish the emotional rewards that can interfere in the maintenance of abstinence from drug addiction including smokeless tobacco addiction.

"Unfortunately, relapse rates after achieving abstinence, in addiction disorders including smokeless tobacco are very high. CV Sciences is pioneering the development of a synthetic, pharmaceutical-grade CBD as an adjunct to nicotine replacement therapy (NRT) for the treatment of smokeless tobacco addiction," commented Amy McCord, Ph.D., Director of Drug Development for CV Sciences. "Currently, there are no approved drugs for the treatment of this addiction, which affects 8 million adults in the US. As we are moving along with the commercialization of our drug candidate, CVSI-007, we are discovering more research that support the scientific knowledge about the positive effects of CBD on helping people with their addiction."

About Amy McCord, Ph.D.

Dr. Amy McCord has an academic and research background in microbiology and cell biology, cancer biology, and drug discovery. Dr. McCord worked as a regulatory affairs manager for multiple small biotech companies, specializing in CMC of complex biological molecules and small molecules. She later became a full-time regulatory affairs and CMC consultant and has gained experience over the years with a wide variety of formulations and product types for both small biotech companies and established pharmaceutical companies. In particular, Dr. McCord has experience assisting early-phase companies to prepare for human clinical trials and submit Investigational New Drug (IND) applications to FDA. Dr. McCord holds a Ph.D. in microbiology from the University of South Florida and has authored multiple peer-reviewed manuscripts and abstracts. She currently serves as the Director of Drug Development at CV Sciences.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from or by visiting


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.


Robert Haag
Managing Director
IRTH Communications

Source: CV Sciences, Inc.